What’s Next For Vaxart Stock After Tough Phase 1 Readout?
1 minuto de lecturaBiotech company Vaxart (NASDAQ: VXRT) posted mixed phase 1 results for its tablet-based Covid-19 vaccine, causing its stock to decline by over 60% from last week’s high. Although the vaccine was well tolerated and produced multiple immune responses, it failed to induce neBiotech company Vaxart (NASDAQ: VXRT) posted mixed phase 1 results for its tablet-based Covid-19 vaccine, causing its stock to decline by over 60% from last week’s high. Although the vaccine was well tolerated and produced multiple immune responses, it failed to induce neRead MoreStocks,US Markets,InvestingStocks Feed
